Total Valuation
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has a market cap or net worth of HK$4.24B. The enterprise value is HK$12.14B.
Market CapHK$4.24B
Enterprise ValueHK$12.14B
Share Statistics
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has 136,218,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding136,218,830
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 4.06%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)4.06%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee401.41M
Profits Per Employee6.47M
Employee Count64
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H is 95.4. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s PEG ratio is ―.
PE Ratio95.4
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow37.83
PEG Ratio―
Income Statement
In the last 12 months, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H had revenue of 25.69B and earned 769.11M in profits. Earnings per share was 0.28.
Revenue25.69B
Gross Profit1.38B
Operating Income1.20B
Pretax Income983.82M
Net Income769.11M
EBITDA1.29B
Earnings Per Share (EPS)0.28
Cash Flow
In the last 12 months, operating cash flow was 676.38M and capital expenditures -346.62M, giving a free cash flow of 329.75M billion.
Operating Cash Flow676.38M
Free Cash Flow329.75M
Free Cash Flow per Share2.42
Dividends & Yields
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H pays an annual dividend of HK$0.025, resulting in a dividend yield of ―
Dividend Per ShareHK$0.025
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.04
52-Week Price Change81.16%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)9.90M
Important Dates
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H as a current ratio of ―, with Debt / Equity ratio of 203.54%
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA9.64
Interest Coverage Ratio―
Taxes
In the past 12 months, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has paid 214.71M in taxes.
Income Tax214.71M
Effective Tax Rate―
Enterprise Valuation
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H EV to EBITDA ratio is 50.49, with an EV/FCF ratio of 24.56.
EV to Sales1.84
EV to EBITDA50.49
EV to Free Cash Flow24.56
EV to Operating Cash Flow24.56
Balance Sheet
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has HK$2.46B in cash and marketable securities with HK$7.54B in debt, giving a net cash position of -HK$5.08B billion.
Cash & Marketable SecuritiesHK$2.46B
Total DebtHK$7.54B
Net Cash-HK$5.08B
Net Cash Per Share-HK$37.30
Tangible Book Value Per Share―
Margins
Gross margin is 5.35%, with operating margin of ―, and net profit margin of ―.
Gross Margin5.35%
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―